{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-001379","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.035745+00:00","generated_at":"2026-05-15T10:33:33.912699+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics","bullets":["Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.","He brings 15+ years experience in oncology diagnostics, previously at Menarini, Congenica, Variantyx, and QIAGEN.","BioNexus holds exclusive commercialization rights for VitaGuard in Southeast Asia through its Fidelion investment.","MRD testing is a fast-growing precision oncology segment for early cancer recurrence detection."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-001379","json":"https://secwatch.observer/filing/0001477932-26-001379.json","markdown":"https://secwatch.observer/filing/0001477932-26-001379.md","text":"https://secwatch.observer/filing/0001477932-26-001379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226001379/0001477932-26-001379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226001379/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:33:33.912699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}